GE Healthcare Technologies Inc

GE Healthcare Technologies Inc(GEHC)股票分析

$69.570

-0.772 (-1.11%)收盘时

Loading chart…
最高
71.320
开盘
71.100
成交量加权均价
70.11
成交量
3.12M
市值
35.98B
最低
69.450
成交额
218.65M
企业价值/息税折旧摊销前利润(TTM)
9.83

GE HealthCare Technologies Inc. is a healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first artificial intelligence (AI)-enabled solutions, services and data analytics. Its business segments include Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). Its Imaging segment offers a portfolio of scanning devices, clinical applications, service capabilities, and digital solutions. Its AVS segment offers ultrasound, image guided therapies, and interventional solutions with a portfolio that spans the continuum of care, including screening, diagnosis, treatment, and monitoring of certain diseases. Its PCS segment consists of patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, maternal infant care, and consumables and services. Its PDx segment develops and produces two types of imaging agents: contrast media and radiopharmaceuticals.

AI 分析 of GE Healthcare Technologies Inc (GEHC)

买入

GE Healthcare Technologies Inc is a good buy right now, trading at $69.57 with a forward P/E of 12.12, indicating it is undervalued compared to its growth potential. The recent acquisition of SOFIE Biosciences for $945 million is expected to enhance revenue growth and market competitiveness, which is a strong positive catalyst. However, the stock has a 1-year change of -7.83%, indicating some volatility and risk.

估值指标

GE Healthcare Technologies Inc(GEHC)当前预期市盈率为 12.12,5 年平均预期市盈率为 17.48。

预期市盈率

严重低估
5 年均值 P/E
17.48
当前P/E
12.12
高估
19.91
低估
15.04

预期 EV/EBITDA

低估
5 年均值 EV/EBITDA
11.34
当前EV/EBITDA
9.83
高估
12.84
低估
9.83

预期市销率

低估
5 年均值 P/S
1.67
当前P/S
1.38
高估
1.95
低估
1.40

Alphio AI 对 GEHC 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%GEHC

$83.18

情景价格

基

基准

基准 · 50%GEHC

$81.20

情景价格

悲

悲观

悲观 · 25%GEHC

$74.35

情景价格

持有 GEHC 的大户

H

Hotchkis and Wiley Capital Management, LLC

+ 持有GEHC

+9.19%

3个月收益率

N

NewEdge Advisors, LLC

+ 持有GEHC

+6.00%

3个月收益率

B

Barrow, Hanley, Mewhinney & Strauss, LLC

+ 持有GEHC

+5.18%

3个月收益率

S

Salem Investment Counselors, Inc.

+ 持有GEHC

+4.26%

3个月收益率

L

Letko, Brosseau & Associates Inc.

+ 持有GEHC

+4.14%

3个月收益率

D

Dodge & Cox

+ 持有GEHC

+2.61%

3个月收益率

事件时间线

2026-10-16 (ET)

09:30:00

GE HealthCare Publishes Anesthesia Study from University of Michigan

2026-10-15 (ET)

08:30:00

GE HealthCare Announces MINItrace Magni Achieves CE Mark

2026-10-05 (ET)

16:30:00

Nasdaq Rises Nearly 300 Points as Market Digests Jobs Report

12:30:00

Nasdaq Rises Nearly 200 Points, Led by Tech Stocks

08:30:00

GE HealthCare Acquires SOFIE Biosciences for $945M

资讯

GEHC 常见问题 —— 由 Alphio AI 解答

GE HealthCare Technologies Inc. is a healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first artificial intelligence (AI)-enabled solutions, services and data analytics. Its business segments include Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). Its Imaging segment offers a portfolio of scanning devices, clinical applications, service capabilities, and digital solutions. Its AVS segment offers ultrasound, image guided therapies, and interventional solutions with a portfolio that spans the continuum of care, including screening, diagnosis, treatment, and monitoring of certain diseases. Its PCS segment consists of patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, maternal infant care, and consumables and services. Its PDx segment develops and produces two types of imaging agents: contrast media and radiopharmaceuticals. It operates in the Healthcare sector (X-RAY APPARATUS & TUBES & RELATED IRRADIATION APPA industry).

GE Healthcare Technologies Inc is a good buy right now, trading at $69.57 with a forward P/E of 12.12, indicating it is undervalued compared to its growth potential. The recent acquisition of SOFIE Biosciences for $945 million is expected to enhance revenue growth and market competitiveness, which is a strong positive catalyst. However, the stock has a 1-year change of -7.83%, indicating some volatility and risk.

暂无帖子

注册或登录后参与讨论

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易